Itch in atopic dermatitis - pathphysiology and treatment

Acta Dermatovenerologica Croatica

Volumn 18, Issue 4, 2010, Pages 289-296

  Ständer, Sonja ^a   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Atopic dermatitis; Histamine 4 receptor; Inter leukin 31; Pruritus; Sensory nerves

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN A; DOXEPIN; EMOLLIENT AGENT; GLUCOCORTICOID; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR AGONIST; HISTAMINE H4 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 31; INTERLEUKIN 6; INTERLEUKIN 8; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTROPHIN 4; PALMIDROL; PIMECROLIMUS; PLACEBO; TACROLIMUS; CANNABINOID; HISTAMINE RECEPTOR; IL31 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ACUPUNCTURE; ATOPIC DERMATITIS; AUTONOMIC NERVOUS SYSTEM; CONTACT ALLERGY; DRUG ACTIVITY; DRUG EFFICACY; EOSINOPHIL; HUMAN; HYPERALGESIA; INFLAMMATORY CELL; LYMPHOCYTE; MAST CELL; NERVE FIBER; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN PRURITUS; SYMPTOMATOLOGY; DRUG POTENTIATION; PHYSIOLOGY;

CANNABINOIDS; DERMATITIS, ATOPIC; EOSINOPHILS; HUMANS; INTERLEUKINS; MAST CELLS; NERVE GROWTH FACTORS; NEUROPEPTIDES; PRURITUS; RECEPTORS, HISTAMINE;

EID: 79957437692     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Hanifn JM, G Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92(Suppl):44-47.
2. Tobin D, Nabarro G, de la Faille HB, van Vlo-ten WA, van der Putte SCJ, Schuurman HJ. Increased number of immunoreactive nerve fbers in atopic dermatitis. J Allergy Clin Immunol 1992;90:613-622.
3. Sugiura H, Omoto M, Hirota Y, Danno K, Ue-hara M. Density and fine structure of peripheral nerves in various skin lesions at atopic dermatitis. Arch Derm Res 1997;289:125-31.
4. Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohis-tochemical and electron microscopic study. Virchows Arch 1998;432:363-370.
5. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990;122:745-750.
6. Tominaga M, Ogawa H, Takamori K. Histologi-cal characterization of cutaneous nerve fbers containing gastrin-releasing peptide in NC/ Nga mice: an atopic dermatitis model. J Invest Dermatol 2009;129:2901-2905.
7. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448(7154):700-703.
8. Williams DH. Skin temperature reaction to his-tamine in atopic dermatitis (disseminated neu-rodermatitis). J Invest Dermatol 1938;1:119-129.
9. Johnson HH, DeOreo GA, Lascheid WP, Mitchell F. Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 1960;34:237-238.
10. Heyer G, Koppert W, Martus P, Handwerker HO. Histamine and cutaneous nociception: histamine-induced responses in patients with atopic eczema, psoriasis and urticaria. Acta Derm Venereol (Stockh) 1998;78:123-126.
11. Heyer G, Hornstein OP, Handwerker HO. Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venerol (Stockh) 1991;71:291-295.
12. Klein PA, Clark RAF. An evidence-based review of the effcacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Der-matol 1999;135:1522-1525.
13. Wahlgren CF, Hägermark Ö, Bergström R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Derm 1990;122:545-551.
14. Dijkstra D, Stark H, Chazot PL, Shenton FC, Leurs R, Werfel T, et al. Human infammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol 2008;128:1696-703.
15. Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, Werfel T. The hista-mine H4 receptor is functionally expressed on T(H)2 cells. 16. J Allergy Clin Immunol 2009;123:619-625.
16. Roßbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, et al. Histamine H(4) receptor antagonism reduces hapten-induced scratching behaviour but not infammation. Exp Dermatol 2009;18:57-63.
17. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachyki-nin receptors in mice. J Pharmacol Exp Ther 1998;286:1140-1145.
18. Pincelli C, Fantini F, Massimi P, Giannetti A. Neuropeptide Y-like immunoreactivity in Lang-erhans cells from patients with atopic dermatitis. Int J Neurosci 1990;51:219-220.
19. Fantini F, Pincelli C, Romualdi P, Donatini A, Giannetti A. Substance P levels are decreased in lesional skin of atopic dermatitis. Exp Der-matol 1992;1:127-128.
20. Ständer S, Siepmann D, Herrgott I, Sunder-kötter C, Luger TA. Targeting the neurokinin receptor 1 with a prepitant: a novel antipruritic strategy. PLoS One. 2010 Jun 4;5:e10968.
21. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA 1987;258:1624-1629.
22. Darsow U, Scharein R, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumor necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997;137:415-417.
23. Martin HA. Bradykinin potentiates the chemo-responsiveness of rat cutaneous C-fbre poly-modal nociceptors to interleukin-2. Arch Phy-siol Biochem 1996;104:229-238.
24. Cremer B, Heimann A, Dippel E, Czarnetzki BM. Pruritogenic effects of mitogen stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venerol (Stockh) 1995;75:426-428.
25. Nordlind K, Chin LB, Ahmed AA, Brakenhoff J, Theodorsson E, Liden S. Immunohistoche-mical localization of interleukin-6-like immuno-reactivity to peripheral nerve-like structures in normal and infamed human skin. Arch Der-matol Res 1996;288:431-435.
26. Bender BG, Ballard R, Canono B, Murphy JR, Leung DY. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol 2008;58:415-420.
27. Kimata H, Lindley I. Detection of plasma in-terleukin-8 in atopic dermatitis. Arch Dis Child 1994;70:119-122.
28. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005;516:180-181.
29. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin infam-mation. J Allergy Clin Immunol 2006;117:411-417.
30. Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Der-matol 2000;114:1108-1112.
31. Kanda N, Koike S, Watanabe A. Prostaglandin E2 enhances neurotrophin-4 production via EP3 receptor in human keratinocytes. J Pharmacol Exp Ther 2005;315:796-804.
32. Dou YC, Hagströmer L, Emtestam L, Johansson O. Increased nerve growth factor and its receptors in atopic dermatitis: an immu-nohistochemical study. Arch Dermatol Res 2006;298:31-37.
33. Toyoda M, Nakamura M, Makino T, Hino T, Ka-goura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Der-matol 2002;147:71-79.
34. Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. J Pharmacol Sci 2005;99:277-286.
35. Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol 2005;115:1268-1275.
36. Melin L, Frederiksen T, Norén P, Swebilius BG. Behavioural treatment of scratching in patients with atopic dermatitis. Br J Dermatol 1986;115:467-474.
37. Fruhstorfer H, Hermanns M, Latzke L. The effects of thermal stimulation on clinical and experimental itch. Pain 1986;24:259-269.
38. Weishaar E, Foster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgetics in atopic eczema. Skin Pharmacol 1997;10:183-90.
39. Lundeberg T, Bondesson L, Thomas M. Effect of acupuncture on experimental induced itch. Br J Dermatol 1987;117:771-777.
40. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997;71:49-55.
41. Wahlgren CF, Scheynius A, Hägermark Ö. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol (Stockh) 1990;70:323-329.
42. Hanifn JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I, effcacy. J Am Acad Dermatol 2001;44: S28-S38.
43. Jekler J, Larkö O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol 1990;22:49-53.
44. Luger T, van Leent EJM, Graeber M, Hed-gecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-794.
45. Hoare C, Li Wan Po A, Williams A. Systemic review of treatment for atopic eczema. Health Technol Assess 2000;4:1-191.
46. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol 1996;35:118-120.
47. Siepmann D, Luger A, Ständer S. [Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.] Hautarzt 2008;6:941-946.
48. Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fbers. Neurosci Res 2004;50:257-262.
49. Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M. Topical pimecrolimus (SDZ ASM 981) and tacrolimus (FK 506) transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007;156:1020-6.
50. Ständer S, Schmelz M, Metze E, Luger TA, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve f-bers and adnexal structures in human skin. J Dermatol Sci 2005;38:177-188.
51. Farquhar-Smith WP, Rice AS. A novel neuroim-mune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hype-ralgesia. Anesthesiology 2003;99:1391-1401.
52. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoyle-thanolamine (ATOPA study). J Eur Acad Der-matol Venereol 2008;22:73-82.
53. Hannuksela M, Kalimo K, Lammintausta K, Turjanmaa K, Vajionen E, Coulie PJ. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993;70:127-133.
54. Drake LA, Millikan LE, and the Doxepin Study Group. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995;131:1403-1408.
55. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Der-matol 1996;34:143-144.
56. Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009;55:40-46.
57. Inagaki N, Shiraishi N, Igeta K, Nagao M, Kim JF, Chikumoto T, et al. Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur J Pharmacol 2010;626:283-289.